Dyslipidemia Drugs Market by Drug Class (Bile Acid Resins, Fibric Acid and Omega-3 Fatty Acid Derivatives, Niacin, Statins, and Other Drugs – Combination Drugs and Cholesterol Absorption Inhibitors) and Forecast 2017-2021

Dyslipidemia Drugs Market by Drug Class (Bile Acid Resins, Fibric Acid and Omega-3 Fatty Acid Derivatives, Niacin, Statins, and Other Drugs – Combination Drugs and Cholesterol Absorption Inhibitors) and Forecast 2017-2021

There are four classes of lipid-lowering drugs in the market: the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (the “statins”), the fibrates (gemfibrozil, clofibrate, and fenofibrate), niacin/nicotinic acid, and the bile acid binding resins (colestipol and cholestyramine). Dyslipidemia is a chronic metabolic syndrome, characterized by improper level of low density lipoprotein, high density lipoprotein, and triglycerides. Dyslipidemia has emerged as a major health concern across the world. The major effects of the lipid lowering drugs include lowering of serum low density lipoprotein (LDL) cholesterol levels which are believed to predispose to atherosclerosis and its complications, acute myocardial infarction, cerebrovascular ischemic stroke and peripheral vascular disease.

The global dyslipidemia drugs market report estimates the market size (Revenue USD million – 2014 to 2021) for key market segments based on the drug class (bile acid resins, fibric acid and omega-3 fatty acid derivatives, niacin, statins, and other drugs such as combination drugs and cholesterol absorption inhibitors), and forecasts growth trends (CAGR% – 2017 to 2021).

The global dyslipidemia drugs market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global dyslipidemia drugs market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.

Major players operating in the global dyslipidemia drugs market and included in this report are Abbott Laboratories, Amgen, Inc., Pfizer, Inc., Novartis AG, Mylan N.V., Merck & Co., Inc., and AstraZeneca plc.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Dyslipidemia Drugs Market

1. Drug Class
1.1. Bile Acid Resins
1.2. Fibric Acid and Omega-3 Fatty Acid Derivatives
1.3. Niacins
1.4. Statins
1.5. Others (Combination Drugs and Cholesterol Absorption Inhibitors)

2. Company Profiles
2.1. Abbott Laboratories
2.2. Amgen, Inc.
2.3. AstraZeneca plc.
2.4. Bayer AG
2.5. Bristol-Myers Squibb Company
2.6. Merck & Co., Inc.
2.7. Mylan N.V.
2.8. Novartis AG
2.9. Pfizer, Inc.
2.10. Shionogi & Co., Ltd.
2.11. Takeda Pharmaceutical Company Limited
2.12. Teva Pharmaceutical Industries Ltd.

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*